- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.06. | Madrigal closes on EU approval of first MASH treatment | ||
| 20.06. | Grail plans FDA filing for cancer blood test after new trial | ||
| 20.06. | Dupixent is first FDA-approved drug for rare skin disease | ||
| 20.06. | FDA blocks trials that send US cells to 'hostile' countries | ||
| 20.06. | Could a Novo error set up early GLP-1 generics in Canada? | ||
| 19.06. | Dismay but little surprise as NICE rejects Alzheimer's drugs | ||
| 18.06. | Gilead's twice-yearly PrEP drug is cleared by FDA | ||
| 18.06. | Amid sector disruption, biotech must focus on 'fundamentals' | ||
| 18.06. | Biogen bids to extend use of Skyclarys to younger patients | ||
| 18.06. | App to support people with depression launches in GB | ||
| 18.06. | Guidance creates access gap in UK for GPP drug Spevigo | ||
| 18.06. | Fired ACIP panel says RFK Jr is weakening vaccine programmes | ||
| 18.06. | UK regulator overhauls medical device regulation | ||
| 18.06. | Welsh biotech Draig emerges with $140m in financing | ||
| 18.06. | FDA unveils fast-track review path for 'national priorities' | ||
| 17.06. | 23andMe fined £2.31m over UK users' genetic data breach | ||
| 17.06. | FDA green lights CSL's once-monthly HAE drug Andembry | ||
| 17.06. | Update: Rumour confirmed as Lilly buys Verve Therapeutics | ||
| 17.06. | Caris swells its planned IPO, seeking $5.7bn valuation | ||
| 17.06. | Is Lilly about to swoop on Verve Therapeutics? | ||
| 17.06. | Genentech's Bittenbender named board chair at BIO | ||
| 16.06. | After rebuffing Biogen, Sage pairs off with Supernus | ||
| 16.06. | J&J says two drugs are better than one in pretreated myeloma | ||
| 16.06. | Former CEO wins bidding war for 23andMe, beating Regeneron | ||
| 16.06. | DMD gene therapy Elevidys linked to new liver failure case |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .